AZD8529 Single Ascending Dose Study

NCT00755378 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2009-03-26

No results posted yet for this study

Summary

This is a study to evaluate safety, tolerability, PK and PD effects of orally administered AZD8529 after single ascending doses

Conditions

  • Healthy Volunteer

Interventions

DRUG

AZD8529

Oral

DRUG

Placebo

Oral

Sponsors & Collaborators

Principal Investigators

  • Sylvan J Hurewitz, MD · AstraZeneca Clinical Pharmacology Unit, US

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00755378 on ClinicalTrials.gov